A new Beginning..., page-2589

He isn't on that much anymore, he's now on average salary, as he should be on at RAP.....NSB has even lower volumes than RAP, much lower.
If he miss out on those 94M shares by 1 year, it's management and his fault anyway for the failed US clinical trials that put the stock back 1 year so there are no-one to blame but themself and it will be a well earn reward for us LT shareholders that 94M shares aren't diluted to the market just when the pps starts to rise with commercialization.